- Home
- BPMC vs IONS Comparison
BPMC vs IONS Comparison
Compare BPMC & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPMC
- IONS
- Stock Information
- Founded
- BPMC 2008
- IONS 1989
- Country
- BPMC United States
- IONS United States
- Employees
- BPMC N/A
- IONS N/A
- Industry
- BPMC Biotechnology: Pharmaceutical Preparations
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- BPMC Health Care
- IONS Health Care
- Exchange
- BPMC Nasdaq
- IONS Nasdaq
- Market Cap
- BPMC 5.8B
- IONS 5.9B
- IPO Year
- BPMC 2015
- IONS 1991
- Fundamental
- Price
- BPMC $128.35
- IONS $43.00
- Analyst Decision
- BPMC Buy
- IONS Buy
- Analyst Count
- BPMC 20
- IONS 16
- Target Price
- BPMC $127.82
- IONS $58.25
- AVG Volume (30 Days)
- BPMC 3.6M
- IONS 2.0M
- Earning Date
- BPMC 07-31-2025
- IONS 07-31-2025
- Dividend Yield
- BPMC N/A
- IONS N/A
- EPS Growth
- BPMC N/A
- IONS N/A
- EPS
- BPMC N/A
- IONS N/A
- Revenue
- BPMC $562,121,000.00
- IONS $717,253,000.00
- Revenue This Year
- BPMC $44.46
- IONS $7.98
- Revenue Next Year
- BPMC $32.78
- IONS $16.09
- P/E Ratio
- BPMC N/A
- IONS N/A
- Revenue Growth
- BPMC 99.19
- IONS N/A
- 52 Week Low
- BPMC $73.04
- IONS $23.95
- 52 Week High
- BPMC $128.52
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- BPMC 74.59
- IONS 78.37
- Support Level
- BPMC $128.06
- IONS $39.37
- Resistance Level
- BPMC $128.52
- IONS $43.71
- Average True Range (ATR)
- BPMC 0.28
- IONS 1.36
- MACD
- BPMC -1.18
- IONS 0.44
- Stochastic Oscillator
- BPMC 74.44
- IONS 92.05
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.